The Ohio University Innovation Center continues its Startup Stories Series with a talk by John Kopchick, world-renowned molecular biologist, on his “bench to bedside” journey from basic scientific discovery to FDA approval of the drug SOMAVERT®.
The event will be held from 11:30 a.m. to 1 p.m. (brown bag lunch) on Thurs., Sept. 7, in room 103 of the Innovation Center, 340 W. State St., Athens.
Kopchick is an Ohio University Distinguished Professor and the Goll-Ohio Eminent Scholar in the Edison Biotechnology Institute and Heritage College of Osteopathic Medicine. He is an internationally recognized leader in the growth hormone field. In his talk, “Growth Hormone, Mini-Mice, Football, Dirty Shorts and a New Drug,” Kopchick will discuss how his research team’s discovery of growth hormone receptor antagonists moved from the lab to the marketplace, including his experience founding a startup company. Since SOMAVERT® hit the market in 2003, Ohio University has received more than $75 million in royalty income.
The Startup Stories Series, held quarterly, is open to the public. It spotlights the success stories of innovators and entrepreneurs experienced with technology commercialization and startup businesses.
“This is a great opportunity to meet new people and find out what’s happening in the startup community,” said Tanya Conrath, associate director of the Innovation Center.
Participants must register online: https://events.r20.constantcontact.com/register/eventReg?oeidk=a07eei6al9o29c86c4c&oseq=&c=&ch = For more information, contact Conrath at 740-593-9346 or email@example.com.